CA-NEXTROLL
AdRoll Group today announced it has rebranded as NextRoll, Inc. , a marketing and data technology company. Additionally, NextRoll is introducing external APIs to open its infrastructure, technology and data to a wide array of new companies. NextRoll is now comprised of three business units: RollWorks , an account-based platform for B2B marketing and sales teams; AdRoll , a growth marketing platform for direct-to-consumer (DTC) brands; and NextRoll Platform Services , a marketing-technology-as-a-service offering for brands, agencies, marketplaces, publishers, and marketing platforms to enhance current marketing capabilities or enable new revenue streams.
As online marketing has become more complex, many companies must choose between building their own technology stacks or working with closed-system providers, which can result in losing control, flexibility and customer insight. Now, with NextRoll Platform Services, companies can access leading marketing technology, data and channels without sacrificing relationships with their key audiences. For example, marketplaces can improve demand generation by giving their customers access to premium tools and audiences from NextRoll.
NextRoll Platform Services leverages rich data assets for unified, people-based profiles across first-, second- and third-party data, including more than 500 million identities and 1 billion devices. Additionally, NextRoll’s machine-learning capabilities enable companies to provide marketing messages, activate curated audiences and measure which efforts drive the greatest impact. NextRoll Platform Services customers can scale as needed, with a global infrastructure that covers 110 countries and manages up to five petabytes of stored data and 12 trillion real-time events processed daily.
“We’ve built an unrivaled marketing and data technology stack that enables marketers to better understand and engage with their audiences to make measurable decisions,” said Toby Gabriner, CEO of NextRoll. “With our new NextRoll Platform Services, we can offer these benefits to more companies, and allow them to innovate on top of our offerings. As we launch NextRoll Platform Services, it’s clear we’ve grown beyond our old name. Today, NextRoll is a marketing and data technology company.”
Services available today include:
Channels-as-a-Service
Channels-as-a-Service from NextRoll Platform Services allows businesses to expand their marketing solutions to new channels, including display ads, social media, native ads, email and video across devices enabling their customers to attract and re-engage audiences. With integrations to over 20 publishers and exchanges from Channels-as-a-Service, users can access the best inventory at any time to accelerate budget fulfillment and hit performance goals. They also gain granular insights into conversion, audience, performance and delivery data.
Audiences-as-a-Service
Many companies end up with vast amounts of raw audience data that is difficult to comprehend. With Audiences-as-a-Service from NextRoll Platform Services, companies have a unified and normalized view across identities and platforms within their existing data set, turning data into targetable segments they can ingest at scale and use in real-time. With this view, companies can better understand and serve each customer or segment. Companies can also enrich internal user profiles by leveraging the NextRoll database or package up these audience insights into premium, targetable segments for resale.
NextRoll Platform Services currently has 10 large customers that drive nearly $1 million in revenue per month, and has significant traction in the pipeline. A key contributor to the momentum is an existing joint venture with Rakuten in the Japanese market that leverages NextRoll Platform Services.
NextRoll Platform Services will release additional offerings in 2020 and beyond. Developers can access integration toolkits here .
About NextRoll
NextRoll, Inc. is a marketing and data technology company on a mission to accelerate growth for companies, big and small. Since 2007, our technology has powered a suite of data-driven marketing solutions and services. NextRoll Platform Services offer marketing-technology-as-a-service for brands, agencies, marketplaces, publishers and marketing platforms, to create more value for their business. Ambitious DTC brands use AdRoll products to make their display, social, and email advertising work together to accelerate business growth. RollWorks offers ambitious B2B companies an account-based platform to align their marketing and sales teams and confidently grow revenue. NextRoll empowers over 37,000 customers worldwide to understand, attract and engage buyers, driving growth for their businesses.
NextRoll is a privately-held company headquartered in San Francisco, CA. Company products honor the best practices for data use and privacy of leading associations including the Network Advertising Initiative (NAI) and the Digital Advertising Alliance’s (DAA) App Choices programs. Learn more about NextRoll at nextroll.com
AdRoll, NextRoll and RollWorks are trademarks NextRoll.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005355/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom